Detalhe da pesquisa
1.
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Invest New Drugs
; 32(3): 510-7, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395457
2.
A Phase I, Randomized, Multi-Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants.
Clin Pharmacol Ther
; 115(5): 1075-1084, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38159266
3.
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Bioorg Med Chem Lett
; 23(10): 3059-63, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23566514
4.
Synthesis and structure based optimization of novel Akt inhibitors.
Bioorg Med Chem Lett
; 18(11): 3359-63, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18456494
5.
The Hedgehog signaling pathway as a target for anticancer drug discovery.
Curr Top Med Chem
; 5(2): 147-57, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15853643
6.
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Clin Cancer Res
; 21(8): 1888-95, 2015 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25652454
7.
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
ACS Med Chem Lett
; 3(2): 106-11, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900436
8.
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
MAbs
; 4(6): 710-23, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23007574
9.
Design of selective, ATP-competitive inhibitors of Akt.
J Med Chem
; 53(12): 4615-22, 2010 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20481595